Lupus & antiphospholipid syndrome
Comparison of efficacy of continuous mycophenolate mofetil with sequential cyclophosphamide and tacrolimus as maintenance therapy for lupus nephritis
Authors' conclusion
MMF has potential as an effective treatment for renal manifestations in Japanese patients throughout induction and maintenance therapies for LN, as an alternative to conventional IVCY-TAC therapy, and as a glucocorticoid-sparing agent.
Study context
- Population
- Japanese patients with lupus nephritis (LN)
- Participants
- 14 vs 10
- Exposure
- Continuous mycophenolate mofetil (MMF) vs monthly intravenous cyclophosphamide (IVCY) followed by tacrolimus (TAC) as induction and maintenance therapy for LN
- MMFn = 14
- IVCY-TACn = 10reference
- Outcome
- Renal response (therapeutic effects on renal manifestations and serological findings)
- Follow-up
- 36 months
Main finding
As reported in the abstract
Mean urine protein-to-creatinine ratio, change from baseline
- MMF: significantly decreased from 2.75 to 0.11 g/gCr
- IVCY-TAC: significantly decreased from 3.26 to 0.22 g/gCr
- Efficacy was similar between the MMF and IVCY-TAC groups
Observational data: associations, not effects.
Further findings
Serum immunological variables (C3 or C4, anti-dsDNA titer), SLE disease activity index and daily prednisolone dose
- Significant improvements in both groups during induction, maintained during maintenance therapy
Original publication
Comparison of efficacy of continuous mycophenolate mofetil with sequential cyclophosphamide and tacrolimus as maintenance therapy for lupus nephritis. Lupus. Published 17 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →